Home | Register | Login | Inquiries | Alerts | Sitemap |  


Advanced Search
JKM > Volume 43(2); 2022 > Article
Lee, Hwang, Lee, Yim, Jung, Park, Park, Ko, and Cho: Two Cases of Korean Medicine Treatment for Patients Complaining of Long-lasting Discomfort after COVID-19 Vaccination

Abstract

Objectives

This study examined the effectiveness of Korean medical treatment for two patients complaining of discomfort after receiving Pfizer COVID-19 vaccine.

Methods

The patients were hospitalized for 50 days and 12 days, respectively. They were treated with herbal medicine, acupuncture, electroacupuncture, and moxibustion. We used the Numerical Rating Scale (NRS) on numbness in extremities and headache, Manual Muscle Testing Grading System (MMT), Criteria for Sweating Categorization, and 36-Item Short Form Health Survey (SF-36) to evaluate the clinical effects of the treatment.

Results

In Case 1, headache improved from peak NRS 9 and average NRS 7 on admission day to both NRS 3 on discharge. The SF-36 score was also increased, suggesting that the quality of life was improved. In Case 2, numbness in the extremities improved from NRS 8 on the day before admission to NRS 2 on discharge, and general condition also improved.

Conclusions

This study suggests that Korean medicine can be an effective treatment for patients who experience long-lasting discomfort after being vaccinated with COVID-19, but with no abnormal findings in the examination.

Fig. 1
Changes of NRS Scores for Headaches
*The NRS (Numerical rating scale) score was a self-assessment of the patient’s headache severity.
jkm-43-2-124f1.gif
Fig. 2
Changes of Sweating
*Grade 0 (No hyperhidrosis): No sweat at all.
Grade 1 (Mild hyperhidrosis): The skin is moderately moist.
Grade 2 (Moderate hyperhidrosis): Pearls of sweat form on the skin.
Grade 3 (Severe hyperhidrosis): Sweat drips.
jkm-43-2-124f2.gif
Fig. 3
Changes of Numbness in Extremities During Day and Night Time (A) Upper Extremity Numbness (B) Lower Extremity Numbness
* Numerical Rating Scale
One day before admission
Day of admission
jkm-43-2-124f3.gif
Fig. 4
Manual Muscle Testing Grading System (MMT) Grade of Upper and Lower Extremities
jkm-43-2-124f4.gif
Fig. 5
Self-evaluation of General Weakness
*The score is a subjective rating scale on general weakness.
A score of 0 indicates the lowest level of energy, and 100 indicates the highest level of energy.
jkm-43-2-124f5.gif
Table 1
The Composition of Gwankeibujalijung-tang
Herbal name Botanical name Amount(g)
人蔘 Ginseng Radix 12
白朮 Atractylodis Macrocephalae Rhizoma 8
乾薑(炮) Zingiberis Siccatum Rhizoma Preparat 8
肉桂 Cinnamomi Cortex 8
生薑 Zingiberis Rhizoma 6
大棗 Zizyphi Fructus 6
附子(炮) Aconiti Iateralis Preparata Radix Preparat 4
白芍藥 Paeoniae Radix 4
甘草(炙) Glycyrrhizae Radix Boiled 4

* 위 용량은 1첩을 기준으로 함.

Table 2
The Composition of Geopung-tang
Herbal name Botanical name Amount(g)
生薑 Zingiberis Rhizoma 12
半夏 Pinelliae Tuber 8
桂枝 Cinnamomi Ramulus 8
白朮 Atractylodis Macrocephalae Rhizoma 4
白芍藥 Paeoniae Radix 4
靑皮 Citrii Reticulatae Viride Pericarpium 4
甘草(炙) Glycyrrhizae Radix Boiled 4
枳殼 Aurantii Fructus 4
陳皮 Citri Pericarpium 4
南星 Arisaematis Rhizoma 4
烏藥 Linderae Radix 4

* 위 용량은 1첩을 기준으로 함.

Table 3
The Composition of Gagamgunja-tang
Herbal name Botanical name Amount(g)
香附子 Cyperi Rhizoma 20
白何首烏 Cynanchi Wilfordii Radix 8
黃芪 Astragali Radix 8
白芍藥 Paeoniae Radix 6
當歸 Angelicae Gigantis Radix 6
山藥(炒) Dioscoreae Rhizoma Baked 6
白朮 Atractylodis Macrocephalae Rhizoma 4
川芎 Cnidii Rhizoma 4
大棗 Zizyphi Fructus 4
甘草(炙) Glycyrrhizae Radix Boiled 4
玄胡索 Corydalis Tuber 4
陳皮 Citri Pericarpium 4
生薑 Zingiberis Rhizoma 4
砂仁 Amomi Fructus 4
蔓荊子 Viticis Fructus 3
蘇葉 Perillae Folium 3
細辛 Asari Herba Cum Radice 2

* 위 용량은 1첩을 기준으로 함.

Table 4
The Composition of Seungyangikki-tang
Herbal name Botanical name Amount(g)
白灼藥 Paeoniae Radix 8
桂枝 Cinnamomi Ramulus 8
黃芪 Astragali Radix 8
人蔘 Ginseng Radix 8
大棗 Zizyphi Fructus 6
生薑 Zingiberis Rhizoma 6
白何首烏 Cynanchi Wilfordii Radix 4
當歸 Angelicae Gigantis Radix 4
甘草 Glycyrrhizae Radix 4
肉桂 Cinnamomi Cortex 4

* 위 용량은 1첩을 기준으로 함.

Table 5
Criteria for Sweating Categorization
Grade for excessive sweating Grade
No excessive perspiration 0
Skin moist with perspiration 1
Perspiration oozing from the skin 2
Perspiration dripping from the skin 3
Table 6
Changes of SF-36 Scores
SF-36 Subscale Day 1 Day 50
PF 0 35
RP 0 0
BP 0 42.5
GH 65 65
VT 0 0
SF 0 0
RE 100 100
MH 76 100

PF, Physical function; RP, Role limitation due to physical health problems; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social function; RE, Role limitation due to physical emotional problems; MH, Mental health

Table 7
Prescription of Western Medicine
Medicine Method Dose
Concor tab. 2.5mg qd 1/2
Novasc tab. 5mg qd 1
Rosuzet tab. 10/10mg qd 2/3
Pidogul tab. 75mg qd 1
Cal-D 3 tab. qd 1

* qd, quaque die

참고문헌

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. 2020; A Novel Coronavirus from Patients with Pneumonia in China. N Engl J Med. 382:8. 727–33. http://doi.org/10.1056/NEJMoa2001017
crossref pmid pmc

2. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard [Internet]. Geneva (Switzerland): WHO;2022. [cited 2022 Mar 1]. Available from: https://covid19.who.int/table


3. Korea Disease Control and Prevention Agency. COVID-19 [Internet]. Sejong: Ministry of Health and Welfare;2022. [cited 2022 Mar 1]. Available from: http://ncov.mohw.go.kr/


4. Choi WS. 2021; Comprehensive Understanding and Field Application of COVID-19 Vaccine. Korean J Med. 96:3. 155–9. http://doi.org/10.3904/kjm.2021.96.3.155
crossref

5. Korea Disease Control and Prevention Agency. COVID-19 vaccines [Internet]. Cheongju: Korea Disease Control and Prevention Agency;2022. [cited 2022 Feb 24]. Available from: https://ncv.kdca.go.kr/


6. World Health Organization (WHO). Regional Office for the Western Pacific. Immunization safety surveillance. Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila, 1999 [Internet]. Geneva (Switzerland): WHO;2021. [cited 2021 May 7]. Available from: https://apps.who.int/iris/bitstream/handle/10665/208312/9290611820_eng.pdf?sequence=1&isAllowed=y


7. 전국한의과대학폐계내과협의회. 코로나바이러스감염증-19 한의지료 지침. 제2.1판2020. p. 1–13.


8. 사단법인대한한의사협회. 코로나바이러스감염증-19 한의진료 권고안. 제2판. 2020. p. 1–52.


9. Song JH, Park SY. 2021; A Case of Recurrent Herpes Zoster after Coronavirus. J Korean Med Ophthalmol Otolaryngol Dermatol. 34:4. 181–97. https://doi.org/10.6114/jkood.2021.34.4.181


10. Hölzle E, Hund M, Lommel K, Melnik B. 2010; Recommendations for tap water iontophoresis. JDDG - J Ger Soc Dermatology. 8:5. 379–83. http://doi.org/10.1111/j.1610-0387.2009.07250.x
crossref pmid

11. Lee BY, Lee HJ, Kim JW, Choi HY, Kim YJ, Park JM, et al. 2016; The Efficacy of Shihogayonggolmoryo-tang in Combating Excessive Sweating in Heart Disease Syndrome, Called 心病 in Korean Medicine. J Int Korean Med. 37:4. 601–8. https://doi.org/10.22246/jikm.2016.37.4.601
crossref

12. Ware JE, Gandek B. 1998; Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol. 51:11. 903–12. https://doi.org/10.1016/S0895-4356(98)00081-X
crossref pmid

13. Nam BH, Lee SW. 2003; Testing the validity of the Korean SF-36 Health Survey. J of the Korean Society of Health Statistics. 28:2. 3–24.


14. Lee YJ, Sohn SS. 2014; The Difference of Quality of Life on Blood Stasis Using SF-36. J Korean Obstet Gynecol. 27:4. 15–24.
crossref

15. Korea Centers for Disease Control and Prevention. 2020. Guidelines for management on surveillance of adverse events following immunization. Cheongju (Korea): Korea Centers for Disease Control and Prevention.


16. Jung EH. 2021; Coronavirus disease 2019 vaccines and relevant adverse reactions. Allergy Asthma Respir Dis. 9:3. 124–135. http://doi.org/10.4168/aard.2021.9.3.124
crossref

17. Ahn SH, Lee SH. 2021; Updates on Coronavirus Disease 19 Vaccines and Its Clinical Application. Korean J Fam Pract. 11:4. 236–246. https://doi.org/10.21215/kjfp.2021.11.4.236
crossref

18. Kang SW, Hong SE, Park JW, Kwon SW, Yoon SH, Kim KI, et al. 2021; Safety of Korean Medicine Treatment in Patients Vaccinated with the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19/AZD1222): A Case Series. J Int Korean Med. 42:4. 590–604. https://doi.org/10.22246/jikm.2021.42.4.590
crossref

19. Han JH, Kim DG, Lee JY. 2014; A Case Report of Extensive Limb Swelling in Newborn After Vaccination: Unusual Thigh Swelling After Hepatitis B vaccination. J Int Korean Med. 28:1. 52–60. https://doi.org/10.7778/jpkm.2014.28.1.052


20. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020; Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 383:27. 2603–15. http://doi.org/10.1056/NEJMoa2034577
crossref pmid pmc

21. Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. 2021; Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 3:3. 1–10. https://doi.org/10.1093/braincomms/fcab169
crossref pmid pmc

22. 박인상 . 우천경험요결. 1판. 경기도 고양시: 소나무;2016. p. 82


23. 이광재 . 사상체질과 임상편람 제2권. 2판. 서울: 한미의학;2010. p. 210–216.


24. 류두저우 . 유도주 상한론강의 1. 1판. 경기도 파주시: 물고기숲;2014. p. 109–113.


25. Dalpke A, Helm M. 2012; RNA mediated toll-like receptor stimulation in health and disease. RNA Biology. 9:6. 828–842. https://doi.org/10.4161/rna.20206
crossref pmid pmc

26. Kim TG, Park SM, Kang H, Shim BS, Kim SH, Choi SH, et al. 2008; Effect of Baekhasuoyijung-Tang on Mouse T Cell Cytokines. Korean J Oriental Physiology & Pathology. 22:4. 754–61.


27. Filshie Jacqueline, White Adrian, Cummings Mike. Medical Acupuncture: A Western Scientific Approach. 2nd edition. Seoul: HANMI Medical Publishing Co;2019. p. 40


TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
PubReader  PubReader
Download Citation  Download Citation
  E-Mail
  Print
Share:      
METRICS
0
Crossref
264
View
24
Download
Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953.journal@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Developed in M2PI